Clinical trial registry record

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 12, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05088356
Last registry update
May 12, 2026
Status
Active Not Recruiting
Phase
Phase 1
Sponsor
Stanford University
Enrollment
66
Countries
United States
Match confidence
62%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
66
Population
ALL · 18 Years to 75 Years
Duration
2021-09-07 to 2028-05-01
Intervention
Purified regulatory T-cells (Treg) plus CD34+ HSPC; Fludarabine; Melphalan; CliniMACS CD34 Reagent System; Tacrolimus; Cyclophosphamide; Plerixafor; Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent; Thiotepa; Mycophenolate Mofetil (MMF); Ruxolitinib; Sirolimus
Comparator
Not reported
Outcomes measured
Determine the GVHD-free relapse-free survival (GRFS) post-HCT ( Arm-A) — 12 months; Determine the overall survival (OS) post-HCT ( Arm-B) — 2 years; Incidence of Grade III-IV acute GVHD — At baseline, day +30, 60, 90, 180, year 1 and year 2; The incidence and timing of primary graft failure — 2 years from the Day 0 (day of CD34+ peripheral blood stem cell inf…; Donor CD3 chimerism at Day+60 post-HCT — 2 years from the Day 0 (day of CD34+ peripheral blood stem cell infusion); GVHD-relapse-free survival — 12 months; Overall survival — 12 months; Secondary graft failure — from Day 0 through 100 days; Treatment-emergent adverse events (TEAs) — from Day 0 through 100 days; Acute GVHD (all grades) — from Day 0 through 100 days; Steroid-refractory acute GVHD — within 3-5 days of therapy onset; Non-relapse mortality (NRM) — 12 months; Disease-free survival (DFS) — 12 months; Chronic GVHD (limited or extensive) — from Day 0 through Year 2
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 62% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 62%Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON